

Press release

Lund November 16th, 2018

EQL Pharma AB (publ)

Org.no. 556713-3425



NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.

EQL Pharma's rights issue subscribed to approximately 161.7 percent

The subscription period for the rights issue in EQL Pharma AB (publ) ("EQL Pharma" or the "Company") ended on November 13th, 2018 and the summary shows that the rights issue was subscribed to approximately 161.7 percent. Subscription by exercise of subscription rights amounted to approximately 99.3 percent and subscription without exercise of subscription rights amounted to approximately 62.4 percent of the offered shares. The rights issue raises proceeds of approximately MSEK 24.9 before issue costs of approximately MSEK 1.7. The underwriting commitments have therefore not been utilized.

Allotment of shares subscribed for without exercise of subscription rights has been made in accordance with the principles stated in the information memorandum which has been prepared by reason of the rights issue and which was published on October 29th, 2018. Notification of allotment of shares subscribed for without exercise of subscription rights will within shortly be sent to those who have been allotted shares. The shares shall be paid for in accordance with the instructions on the contract note.

The share capital after the rights issue amounts to SEK 1,307,862.45, distributed on 29,063,610 shares. Trading in paid subscribed shares (EQL BTA) is made on Spotlight Stock Market until the rights issue has been registered with the Swedish Companies Registration Office (Sw. *Bolagsverket*). The registration is expected to be completed during November 2018.

Financial and legal advisors

Västra Hamnen Corporate Finance AB is financial advisor and Setterwalls Advokatbyrå AB is legal advisor to EQL Pharma in connection with the rights issue.

For further information, please contact:

Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

This information is information which EQL Pharma AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on November 16th, 2018.

Press release

Lund November 16th, 2018

EQL Pharma AB (publ)

Org.no. 556713-3425



About EQL Pharma

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets 10 niche generics in the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (7) people and is listed on Spotlight Stock Market. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in EQL Pharma. Any invitation to the persons concerned to subscribe for shares in EQL Pharma was only made through the information memorandum that the Company published on October 29th, 2018.

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa, or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded or reproduced in a manner that contravenes such restrictions or would entail such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or shares have or will be registered under the U.S. Securities Act of 1933, as amended, ("Securities Act"), or securities legislation in any state or other jurisdiction in the United States and may not be offered or sold, directly or indirectly, in or into the United States, except pursuant to an available exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect EQL Pharma's current view on future events and financial and operational development. The words "intend", "estimate", "expect", "may", "plan", "anticipate" or similar expressions regarding indications or prognoses of future developments or trends and which are not statements based on historical facts constitute forward-looking information. Forward-looking statements are in its nature involved with both known and unknown risks and uncertainties, since it is depending on future events and circumstances. Forward-looking statements do not constitute any representations and warranties and the outcome could differ materially from the information set out in the forward-looking statements.